Development and Validation of a LC-MS/MS Assay for the Quantification Of Efavirenz In Different Biological Matrices

Abstract

Aim: The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances, depression and even psychosis.

Results: The investigation of efavirenz distribution required the development of a versatile and sensitive method. In addition to plasma, quantification was required in brain tissue and phosphate-buffered saline. The assay presented here was linear from 1.9 to 500 ng/ml. Accuracy and precision ranged between 93.7 and 99.5%, and 1.5 and 5.6%, respectively.

Discussion: The method developed here represents a versatile, sensitive and easy-to-use assay. The assay has been applied to in vitro and in vivo samples demonstrating reliable efavirenz quantification in multiple matrices.

Citation

(2016). Development and Validation of a LC-MS/MS Assay for the Quantification Of Efavirenz In Different Biological Matrices. Bioanalysis, 2125-2134. https://doi.org/10.4155/bio-2016-0021

• Acceptance Date: Sep 9, 2016
• Publication Date: Oct 1, 2016
• Journal: Bioanalysis
• Print ISSN: 1757-6180
• Publisher: Future Science
• Pages: 2125-2134
• DOI: https://doi.org/10.4155/bio-2016-0021
• Keywords: LC–MS/MS, brain tissue, efavirenz, plasma, protein binding
• Publisher URL: http://dx.doi.org/10.4155/bio-2016-0021